Zojwalla Naseem 4

What Happened

• Naseem Zojwalla, Chief Medical Officer of Olema Pharmaceuticals (OLMA), received two equity awards on February 2, 2026 totaling 356,250 derivative shares: 250,000 time‑based awards and 106,250 performance‑based awards. Each grant is reported at $0.00 per share (award/derivative), so no cash was exchanged.

Key Details

• Transaction date: 2026-02-02; filing date: 2026-02-04 (appears timely — Form 4s are generally due within 2 business days).
• Reported price: $0.00 per share; total reported cash value: $0.
• Shares reported: 250,000 (time‑based) + 106,250 (performance‑based) = 356,250 derivative awards.
• Shares owned after the transaction: not disclosed in this Form 4.
• Footnote summary:
  • F1 (time‑based): 25% of the option grant vests on Feb 2, 2027, then 1/48 of the total vests monthly thereafter, subject to continued service.
  • F2 (performance‑based): The 106,250 awards vest only if Olema's stock reaches pre‑set price thresholds during one of two performance periods (Feb 2, 2026–Dec 31, 2029 and Feb 2, 2026–Dec 31, 2030). Vesting occurs after Compensation Committee certification of threshold achievement and is subject to continued service.
• Transaction type code: A = Grant/Award (derivative security).

Context

• These are equity awards (derivative/option‑style) granted as compensation — not open‑market purchases or sales — and do not represent immediate cash proceeds or sales of stock. Performance awards depend on stock‑price targets measured by a 30‑day average and on continued employment; time‑based awards vest over several years. For retail investors, grants signal potential future alignment of executive pay with company performance but do not by themselves indicate buying or selling pressure.